A Degenerate HLA-DR Epitope Pool of HER-2/neu Reveals a NovelIn vivoImmunodominant Epitope, HER-2/neu88-102
Authors:
- 1 February 2010
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 16 (3) , 825-834
Abstract
Purpose: Over the past two decades, there has been significant interest in targeting HER-2/neu in immune-based approaches for the treatment of HER-2/neu+ cancers. For example, peptide vaccination using a CD8 T cell–activating HER-2/neu epitope (amino acids 369-377) is an approach that is being considered in advanced phase clinical trials. Studies have suggested that the persistence of HER-2/neu–specific CD8 T cells could be improved by incorporating human leukocyte antigen (HLA) class II epitopes in the vaccine. Our goal in this study was to identify broad coverage HLA-DR epitopes of HER-2/neu, an antigen that is highly expressed in a variety of carcinomas. Experimental Design: A combination of algorithms and HLA-DR–binding assays was used to identify HLA-DR epitopes of HER-2/neu antigen. Evidence of preexistent immunity in cancer patients against the identified epitopes was determined using IFN-γ enzyme-linked immunosorbent spot (ELIspot) assay. Results: Eighty-four HLA-DR epitopes of HER-2/neu were predicted, 15 of which had high binding affinity for ≥11 common HLA-DR molecules. A degenerate pool of four HLA-DR–restricted 15-amino acid epitopes (p59, p88, p422, and p885) was identified, against which >58% of breast and ovarian cancer patients had preexistent T-cell immunity. All four epitopes are naturally processed by antigen-presenting cells. Hardy-Weinberg analysis showed that the pool is useful in ∼84% of population. Lastly, in this degenerate pool, we identified a novel in vivo immunodominant HLA-DR epitope, HER-2/neu88-102 (p88). Conclusion: The broad coverage and natural immunity to this epitope pool suggests potential usefulness in HER-2/neu–targeting, immune-based therapies such as vaccines. Clin Cancer Res; 16(3); 825–34Keywords
This publication has 35 references indexed in Scilit:
- Identification of a broad coverage HLA-DR degenerate epitope pool derived from carcinoembryonic antigenCancer Immunology, Immunotherapy, 2009
- The Impact of HER2/neuExpression Level on Response to the E75 Vaccine: From U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02Clinical Cancer Research, 2009
- Current perspective – TrastuzumabEuropean Journal of Cancer, 2009
- DNA Vaccination Controls Her-2+ Tumors that Are Refractory to Targeted TherapiesCancer Research, 2008
- An HLA-DR–Degenerate Epitope Pool Detects Insulin-like Growth Factor Binding Protein 2–Specific Immunity in Patients with CancerCancer Research, 2008
- Multiple roles for CD4+ T cells in anti‐tumor immune responsesImmunological Reviews, 2008
- Combined Clinical Trial Results of a HER2/neu(E75) Vaccine for the Prevention of Recurrence in High-Risk Breast Cancer Patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02Clinical Cancer Research, 2008
- T-Cell Immunity to the Folate Receptor Alpha Is Prevalent in Women With Breast or Ovarian CancerJournal of Clinical Oncology, 2006
- Investigating the Combination of Trastuzumab and HER2/neu Peptide Vaccines for the Treatment of Breast CancerAnnals of Surgical Oncology, 2006
- Adoptive immunotherapy for cancer: building on successNature Reviews Immunology, 2006